BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Angel Medical Systems Raises $27.5 Million


12/17/2012 7:49:01 AM

SHREWSBURY, N.J., Dec. 17, 2012 /PRNewswire/ -- Angel Medical Systems, Inc., a privately held medical device company developing technologies for continuous intracardiac ischemia monitoring and alerting, announced today that it completed an initial closing of an aggregate $27.5 million financing.

Participants in the round included existing venture capital, strategic partner and angel investors, as well as a new investor group, SOAM Angel Partners, LLC. Concurrent with the financing, Dr. Victor Whitman, a principal at SOAM Angel Partners, joined AngelMed's board of directors, which includes prominent medical industry veterans and financial partners.

The funding will be used to complete the company's Phase II Pivotal Trial of the AngelMed GuardianĀ® System. Additionally, funds will be used for research and development of its next generation ischemia monitoring device, and continued expansion and commercialization in Europe and Brazil.

"We've made significant progress in our Pivotal Trial of the Guardian System, with more than 660 patients implanted with the device in the United States," said Dr. David Fischell, Chief Executive Officer of Angel Medical Systems. "This additional capital will enable us to continue study enrollment, and providing efficacy endpoints are met, file our Premarket Approval (PMA) in the coming year."

More than 1.3 million people have a heart attack every year, and more than 1/3 of those individuals either don't recognize symptoms or delay seeking care for three hours or more, resulting in significant heart damage or death. The AngelMed Guardian System heart monitor is designed to track significant changes in the heart's electrical signal, identify the signature of acute thrombotic occlusions, and then alert the patient to seek immediate medical attention.

"Detecting and warning patients at the earliest stage of coronary occlusion would allow us to shift the paradigm for treatment forward to the onset of the heart attack, which we believe could significantly improve clinical outcomes," added Dr. Fischell.

The AngelMed Guardian System has CE Mark approval in Europe, and is being actively implanted in Germany. The system is also commercially available in Brazil. St. Jude Medical, Inc. has licensed AngelMed's detection algorithm for use in the company's implantable cardioverter defibrillators (ICDs), which are commercially available in Europe, and are currently in U.S. clinical studies.

For more information on Angel Medical Systems, contact Andrew Taylor,
Chief Financial Officer at 732-542-5551, or visit http://www.angel-med.com.

Caution: In the United States, the AngelMed Guardian System is an investigational device. Limited by Federal (or United States) law to investigational use.

Forward looking statements: Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

SOURCE Angel Medical Systems


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->